Retrospective Study

Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study

Zhe-Xuan Wang, En-Xin Wang, Wei Bai, Dong-Dong Xia, Wei Mu, Jing Li, Qiao-Yi Yang, Ming Huang, Guo-Hui Xu, Jun-Hui Sun, Hai-Liang Li, Hui Zhao, Jian-Bing Wu, Shu-Fa Yang, Jia-Ping Li, Zi-Xiang Li, Chun-Qing Zhang, Xiao-Li Zhu, Yan-Bo Zheng, Qiu-He Wang, Jing Li, Jie Yuan, Xiao-Mei Li, Jing Niu, Zhan-Xin Yin, Jie-Lai Xia, Dai-Ming Fan, Guo-Hong Han, on behalf of China HCC-TACE Study Group

ORCID number: Zhe-Xuan Wang (0000-0001-5722-0555); En-Xin Wang (0000-0001-9967-3026); Wei Bai (0000-0001-8954-9187); Dong-Dong Xia (0000-0003-2800-8752); Wei Mu (0000-0001-7817-0008); Jing Li (0000-0002-1594-9361); Qiao-Yi Yang (0000-0001-8244-0138); Ming Huang (0000-0002-4072-7488); Guo-Hui Xu (0000-0002-6119-7949); Jun-Hui Sun (0000-0002-1816-1190); Hai-Liang Li (0000-0003-3556-1482); Hui Zhao (0000-0002-6878-9154); Jian-Bing Wu (0000-0002-4576-7289); Shu-Fa Yang (0000-0001-6338-8872); Jia-Ping Li (0000-0001-7802-7738); Zi-Xiang Li (0000-0001-6789-8677); Chun-Qing Zhang (0000-0001-7748-8719); Xiao-Li Zhu (0000-0002-5504-9528); Yan-Bo Zheng (0000-0001-5409-379X); Qiu-He Wang (0000-0002-5378-8458); Jing Li (0000-0002-3557-7612); Xiao-Mei Li (0000-0003-4156-4251); Jing Niu (0000-0001-7456-8465); Zhan-Xin Yin (0000-0002-4690-7923); Jie-Lai Xia (0000-0002-8077-9047); Dai-Ming Fan (0000-0002-3041-9107); Guo-Hong Han (0000-0003-4568-3776).

Author contributions: Wang ZX and Wang EX contributed equally to this work; Wang ZX, Wang EX and Han GH designed the research; Wang ZX, Wang EX, Xia DD and Bai W performed the research and collected data; Wang ZX, Wang EX analyzed the data;
Validation of prognostic systems for TACE in HCC

Xia DD and Xia JL contributed to statistical support; Wang ZX, Wang EX, Xia DD, Bai W, Mu W, Li J, Yang QY, Huang M, Xu GH, Sun JH, Li HL, Zhao H, Wu JB, Yang SF, Li JP, Li ZX, Zhang CQ, Zhu XL, Zheng YB, Wang QH, Li J, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM and Han GH contributed to administrative, technical, or material support; Wang ZX, Wang EX and Han GH wrote the paper.

Institutional review board statement: The study protocol was reviewed and approved by the institutional Ethics Committees of the First Affiliated Hospital of the Fourth Military Medical University.

Informed consent statement: Patients were not required to give informed consent for this study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

Conflict-of-interest statement: The authors have no conflict of interest to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited Manuscript

Received: November 19, 2019
Peer-review started: November 19, 2019
First decision: December 7, 2019
Revised: January 8, 2020
Accepted: January 15, 2020
Article in press: January 15, 2020
Published online: February 14, 2020

P-Reviewer: Ghosn M, Wang ZJ, El Nakib AMSA
S-Editor: Wang YQ
L-Editor: Webster JR
E-Editor: Zhang YL

University, Qingdao 266000, Shandong Province, China

Chun-Qing Zhang, Department of Gastroenterology and Hepatology, Shandong Province Hospital affiliated to Shandong University, Jinan 250021, Shandong Province, China

Xiao-Li Zhu, Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China

Yan-Bo Zheng, Department of Interventional Radiology, Yantai Yuhuangding Hospital, Yantai 264000, Shandong Province, China

Jie-Lai Xia, Department of Health Statistics, Fourth Military Medical University, Xi’an, Xi’an 710032, Shaanxi Province, China

Corresponding author: Guo-Hong Han, MD, PhD, Professor, Department of Liver Disease and Digestive Interventional Radiology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, 15 West Changle Road, Xi’an 710032, Shaanxi Province, China. hanghi@fmmu.edu.cn

Abstract

BACKGROUND
The treatment outcome of transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC) varies greatly due to the clinical heterogeneity of the patients. Therefore, several prognostic systems have been proposed for risk stratification and candidate identification for first TACE and repeated TACE (re-TACE).

AIM
To investigate the correlations between prognostic systems and radiological response, compare the predictive abilities, and integrate them in sequence for outcome prediction.

METHODS
This nationwide multicenter retrospective cohort consisted of 1107 unresectable HCC patients in 15 Chinese tertiary hospitals from January 2010 to May 2016. The Hepatoma Arterial-embolization Prognostic (HAP) score system and its modified versions (mHAP, mHAP2 and mHAP3), as well as the six-and-twelve criteria were compared in terms of their correlations with radiological response and overall survival (OS) prediction for first TACE. The same analyses were conducted in 912 patients receiving re-TACE to evaluate the ART (assessment for re-treatment with TACE) and ABCR (alpha-fetoprotein, Barcelona Clinic Liver Cancer, Child-Pugh and Response) systems for post re-TACE survival (PRTS).

RESULTS
All the prognostic systems were correlated with radiological response achieved by first TACE, and the six-and-twelve criteria exhibited the highest correlation (Spearman R = 0.39, P = 0.026) and consistency (Kappa = 0.14, P = 0.019), with optimal performance by area under the receiver operating characteristic curve of 0.71 [95% confidence interval (CI): 0.68-0.74]. With regard to the prediction of OS, the mHAP3 system identified patients with a favorable outcome with the highest concordance (C)-index of 0.60 (95%CI: 0.57-0.62) and the best area under the receiver operating characteristic curve at any time point during follow-up; whereas, PRTS was well-predicted by the ABCR system with a C-index of 0.61 (95%CI: 0.59-0.63), rather than ART. Finally, combining the mHAP3 and ABCR systems identified candidates suitable for TACE with an improved median PRTS of 36.6 mo, compared with non-candidates with a median PRTS of 20.0 mo (log-rank test P < 0.001).

CONCLUSION
Radiological response to TACE is closely associated with tumor burden, but superior prognostic prediction could be achieved with the combination of mHAP3 and ABCR in patients with unresectable liver-confined HCC.

Key words: Transarterial chemoembolization; Hepatocellular carcinoma; Prognostic system; Radiological response; Overall survival; Predictive ability
Core tip: There are several prognostic systems for the prediction of treatment outcome following transarterial chemoembolization for hepatocellular carcinoma; however, their discriminatory abilities in real-world patients need to be validated and compared to select the optimal system for clinical decision-making. We found that the six-and-twelve criteria were closely correlated with radiological response, modified Hepatoma Arterial-embolization Prognostic version 3 predicted overall survival best, and ABCR (alpha-fetoprotein, Barcelona Clinic Liver Cancer, Child-Pugh and Response) was a reliable predictive system for post repeated transarterial chemoembolization survival. The sequential combination of these systems performed well in outcome prediction.

INTRODUCTION

According to the Barcelona Clinic Liver Cancer (BCLC) staging system and current treatment guidelines, transarterial chemoembolization (TACE) is the first-line treatment option for intermediate hepatocellular carcinoma (HCC) with asymptomatic, large or multifocal unresectable nodules in the absence of macrovascular invasion (MVI) or extrahepatic metastasis (EHS)[1-3]. However, the treatment outcome of TACE varies greatly, with median survival ranging from 13 to 43 mo[4,5]. Apart from the differences in TACE techniques, it is universally recognized that such a wide variation in survival results from an intrinsic disease heterogeneity including the degree of liver dysfunction, tumor burden and other factors under the general term of “intermediate HCC”, which have not been adequately captured by current staging systems[6,7]. Moreover, the current use of TACE in clinical practice exceeds guideline recommendations, covering not only patients with unresectable early HCC, but also those with liver-confined advanced diseases[8,9].

Several prognostic algorithms have been proposed to address the clinical heterogeneity of HCC patients receiving TACE[10]. Typically, the Hepatoma Arterial-embolization Prognostic (HAP) score was proposed and has been modified into three different versions (mHAP, mHAP2 and mHAP3), and target unresectable HCC patients treated with TACE for outcome prediction[11-13]. However, these prediction systems derived from a highly heterogeneous population, and their predictive values remain controversial in the majority of patients treated with TACE in the real world (patients with unresectable early, intermediate and liver-confined advanced stage). Recently, the “six-and-twelve” (6&12) criteria were proposed by our team to predict treatment outcomes in guideline-recommended patients treated with TACE. This prognostic model was “linear predictor = largest tumor diameter (cm) + tumor number” and could divide patients enrolled into 3 risk stratifications with the cut-off values “6” and “12”, which may provide an easy-to-use tool (a Nomogram developed based on statistical results) for classification and individual survival prediction[5]. However, the prognostic ability of the 6&12 should be investigated in a larger population. In addition, the ART (assessment for re-treatment with TACE) and ABCR (alpha-fetoprotein (AFP), BCLC, Child-Pugh and Response) systems were proposed for outcome prediction of repeated TACE (re-TACE)[15,16]. Despite the development of these prognostic systems, there is no consensus regarding their clinical significance due to the absence of real-world validations and comparisons.

We carried out this nationwide multicenter study with the aim of externally validating the existing prognostic systems for TACE, investigating their correlations with radiological response, comparing their predictive abilities regarding survival and identifying the optimal combination of scoring systems for first TACE and re-TACE in real-world HCC patients.
MATERIALS AND METHODS

Study population
A total of 2978 cases were extracted from a nationwide database of HCC patients treated with TACE at 15 Chinese tertiary hospitals between January 2010 and May 2016. HCC was diagnosed by either histological or imaging evaluations according to the American Association for the Study of Liver Diseases / European Association for the Study of the Liver (AASLD/EASL) guidelines. Patients meeting one of the following criteria were excluded: (1) Any previous HCC-related treatments; (2) Presence of MVI and/or EHS; (3) Child-Pugh score > 7 or decompensation; (4) Eastern Cooperative Oncology Group performance status score > 1; (5) Diffuse tumor; (6) Additional systemic treatment; and (7) Absence of baseline information or imaging. In total, 1107 patients were included, and 912 of these patients received re-TACE (Figure 1). The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional Ethics Committee of the First Affiliated Hospital of the Fourth Military Medical University; patients were not required to give informed consent for this study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

TACE treatment and follow-up
Treatment decisions were made at the discretion of the multidisciplinary liver tumor boards in each enrolled institution on the basis of following treatment guidelines. Before TACE, digital subtraction angiography (DSA) of the hepatic artery was performed to assess the vascular anatomy and tumor vascularity. During TACE, a vascular catheter was selectively inserted into the tumor-feeding artery followed by an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2–20 mL), and then embolization using gelatin sponge particles. Laboratory assessment was carried out every four to six weeks after the procedure. Radiologic evaluation using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) was performed on the fourth and eighth week after TACE and every eight weeks thereafter using contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI). However, in clinical practice, the intensity of follow-up depended on individuals’ baseline characteristics (including kidney function) and responses to the last treatment, i.e., on demand. Thus, not all patients strictly stuck to this imaging follow-up schedule. Moreover, no contrast-induced nephropathy was observed in the current cohort. For patients with residual viable lesions or local and/or distant intrahepatic recurrences during follow-up, on-demand re-TACE sessions were carried out; and TACE therapy was discontinued when persistent disease progression occurred after two sessions according to imaging assessments. Once patients entered advanced stage according to the specialized assessment, they would receive the recommended treatment according to the national guidelines including systemic therapies and best support care. Then, follow-up was continuously conducted by local investigators until a terminal event occurred or loss of follow-up.

Prognostic scoring, risk stratification and candidate identification
According to the baseline characteristics, the prognostic scores based on HAP[11], mHAP[12], mHAP2[13], mHAP3[14] and the 6&12 criteria[5] were calculated, respectively (Table 1). Risk stratification and candidate identification based on HAP, mHAP and mHAP2 were obtained according to previous literature. For comparability, the quartiles and medians of the continuous scores of mHAP3 and the 6&12 criteria were used to divide patients into four risk strata and to distinguish candidates from non-candidates. For outcome prediction after re-TACE, calculation of the predictive score, patient stratification related to death risk, and identification of potential candidates were conducted according to patient characteristics before re-TACE according to ART[15], and ABCR[16]. The outcome evaluation of first TACE treatment was based on overall survival (OS), which was defined as the time from first TACE to death or the end of the study; whereas assessment of re-TACE effectiveness was based on post re-TACE survival (PRTS), which was defined as the time from the second TACE session to death or the end of the study.

Statistical analysis
Categorical variables were described as frequencies and percentages, and continuous data as the median with interquartile range. Median OS was estimated using Kaplan–Meier curves and compared by the log-rank test. The accompanying hazard ratio (HR) was estimated for each prediction system using the Cox proportional hazard regression model. Receiver operating characteristic (ROC) curves were used to evaluate the correlation between prediction systems and radiological response; and
time-dependent area under the ROC curve (AUROC) curves were used to compare the discriminatory abilities for survival at different follow-up time points. The Spearman test and Kappa value were used to evaluate correlation and consistency between prediction systems and response. To determine the optimal prognostic system, the concordance (C)-index and likelihood ratio (LR) were calculated for each predictive score to evaluate the prognostic value regarding OS. Statistical analyses were conducted using SPSS software version 17.0 (SPSS Inc., Chicago, IL, United States) and R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Patient characteristics
The study cohort consisted of 1107 HCC patients receiving at least one session of TACE, and their baseline characteristics are described in Table 2. The median age was 57 years, and hepatitis B virus infection was the main etiology of HCC. In addition, 912 patients with more than one TACE session were included in the analysis of re-TACE. The median number of TACE sessions was 3 in both the whole cohort and in those patients treated with repeated TACE.

Correlations between prediction scores and radiological response
The median scores for HAP, mHAP, mHAP2, mHAP3, and the 6&12 criteria are shown in Table 3. The patients were divided into four groups (grade A, B, C and D) based on the risk score; however, to compare methodology, the quartiles of the mHAP3 (0.05, 0.41, 0.83) and 6&12 criteria (7.5, 9.7, 12.9) were used to divide the patients into four grades of risk stratification. With regard to radiological response, 149 (13.5%) patients had a complete response (CR), 441 (39.8%) had a partial response (PR), 299 had stable disease (SD) and 218 had progressive disease (PD); the response rate (CR and PR) reached 53.3%. Compared with the other scoring systems, the 6&12 criteria had the highest correlation (Spearman R = 0.39, \( P = 0.026 \)) and consistency (Kappa = 0.14, \( P = 0.019 \)) with treatment response to the first TACE. In the ROC analysis, the AUROC of the 6&12 score for predicting treatment response reached 0.71 [95% confidence interval (CI): 0.68-0.74] and 0.66 (95% CI: 0.63-0.69), which was better than those of the other systems (Figure 2A and 2B).

Predictive abilities of the prediction systems for first TACE
According to the prediction systems, patients with A and B grade of risk stratification were considered candidates for TACE; otherwise, they were considered non-
Table 1  Summary of the prognostic scoring systems (points)

| Prognostic system | Constituents                                                                 | Risk stratification | Candidates |
|-------------------|-------------------------------------------------------------------------------|---------------------|------------|
| HAP               | Albumin < 36 g/L                                                               | HAP A               | 0 Yes      |
|                   | AFP > 400 ng/mL                                                                | HAP B               | 1          |
|                   | Tumor diameter > 7 cm                                                          | HAP C               | 2 No       |
|                   | Bilirubin > 17 μmol/L                                                         | HAP D               | 3-4        |
| mHAP              | Albumin < 36 g/L                                                               | mHAP A              | 0 Yes      |
|                   | AFP > 400 ng/dL                                                                | mHAP B              | 1          |
|                   | Tumor diameter > 7 cm                                                          | mHAP C              | 2 No       |
|                   | mHAP D                                                                         | mHAP D              | 3          |
| mHAP2             | Albumin < 36 g/L                                                               | mHAP2 A             | 0 Yes      |
|                   | AFP > 400 ng/mL                                                                | mHAP2 B             | 1          |
|                   | Tumor diameter > 7 cm                                                          | mHAP2 C             | 2 No       |
|                   | Tumor number ≥ 2                                                               | mHAP2 D             | 3-5        |
|                   | Bilirubin > 0.9 mg/dL                                                          |                     |            |
| mHAP3             | The prognostic index (PI) formula: (0.104 × size in cm) + [0.3089 × number (single node = 1; 2-3 nodes = 2; more than three nodes = 3)] + (0.2185 × Log10 AFP in ng/mL) - (0.1506 × Bilirubin in mg/dL) | < Median PI          | Yes        |
|                   |                                                                                | ≥ Median PI         | No         |
| 6&12              | Score = Tumor size in cm + Tumor number                                        | < Median Score      | Yes        |
|                   |                                                                                | ≥ Median Score      | No         |
| ART               | Absence of radiologic response                                                | 0-1.5               | Yes        |
|                   | AST increase >25 %                                                             | 4                   |            |
|                   | Child-Pugh increase: 1 point                                                   | 1.5                 | ≥ 2.5      |
|                   | ≥ 2 points                                                                     | 3                   |            |
| ABCR              | Presence of radiologic response                                                | -3                  | ≤ 2        |
|                   | AFP ≥ 200 ng/mL                                                                | 1                   | Yes        |
|                   | BCLC B                                                                         | 2                   |            |
|                   | BCLC C                                                                         | 3                   | ≥ 3        |
|                   | Child-Pugh increase: ≥ 2 points                                                 | 2                   |            |

BCLC: Barcelona Clinic Liver Cancer; HAP: Hepatoma Arterial-embolization Prognostic; mHAP: Modified HAP; 6&12: Six-and-twelve criteria; ART: Assessment for re-treatment with TACE; ABCR: Alpha-fetoprotein, BCLC stage, Child-Pugh and Response.

candidates (Table 4). Similarly, in the mHAP3 and 6&12 systems, patients in groups A and B were defined as candidates, and those in groups C and D were considered non-candidates. As shown in Table 3, all five prediction systems identified the TACE-candidates with improved OS from non-candidates (P < 0.001). However, the mHAP3 system had the highest discriminatory ability (C-index 0.60, 95% CI: 0.57-0.62), as well as optimal homogeneity within the classification (LR $\chi^2 = 57.5$). More importantly, the mHAP3 system had the highest AUROC according to the time-dependent ROC analysis (Figure 3A). Based on the mHAP3, there were 554 TACE candidates with a median OS of 33.8 mo and 553 non-candidates with a median OS of 17.2 mo; Cox regression analysis also demonstrated that candidates defined by the mHAP3 system had an almost 50% reduced risk of death compared to non-candidates (HR = 0.52, 95% CI: 0.44-0.62, P < 0.001).

Predictive abilities of the scoring systems for re-TACE
Based on the ART score, the 912 available patients were divided into two groups, 646 were candidates and 266 were non-candidates (Table 4). However, no significant difference in PRTS was detected between these two groups of patients (27.0 mo vs 23.7 mo, log-rank test P = 0.222). In the ABCR assessment, the 600 candidates reached a median PRTS of 33.1 mo, which was longer than the 16.4 mo in 312 non-candidates (log-rank test P < 0.001). In addition, the Cox regression analysis showed that the candidates based on the ABCR had a more than 50% reduced risk of death compared with non-candidates (HR = 0.47, 95% CI: 0.39-0.57, P < 0.001). Compared with ART, the ABCR system had a better C-index, LR $\chi^2$, and time-dependent AUROC at any follow-up time point (Table 4 and Figure 3B).

Combination of mHAP3 and ABCR for candidate identification
## Table 2 Baseline characteristics of patients treated with first TACE and before repeated TACE, n (%) / Median [IQR]

| Characteristics                        | Study cohort          |
|----------------------------------------|-----------------------|
|                                        | TACE (n = 1107)      | Re-TACE (n = 912)    |
| Gender                                 |                       |
| Male                                   | 971 (87.7)            | 801 (87.8)           |
| Female                                 | 136 (12.3)            | 111 (12.2)           |
| Age (year)                             | 57 [47-65]            | 57 [47-65]           |
| Etiology                               |                       |
| HBV                                    | 1004 (90.7)           | 832 (91.2)           |
| Non-HBV                                | 103 (9.3)             | 80 (8.8)             |
| Largest tumor diameter, cm             |                       |
| ≤ 7                                    | 459 (41.5)            | 369 (42.7)           |
| > 7-≤ 10                               | 309 (27.9)            | 247 (27.1)           |
| > 10                                   | 339 (30.6)            | 276 (30.2)           |
| Number of tumors                       |                       |
| 1                                      | 556 (50.2)            | 444 (48.7)           |
| 2                                      | 244 (22.0)            | 212 (23.2)           |
| ≥ 3                                    | 307 (27.7)            | 256 (28.1)           |
| Alpha-fetoprotein, ng/mL               |                       |
| < 400                                  | 626 (56.5)            | 523 (57.3)           |
| ≥ 400                                  | 481 (43.5)            | 389 (42.7)           |
| Child-Pugh score                       |                       |
| A5                                     | 823 (74.3)            | 688 (75.4)           |
| A6                                     | 217 (19.6)            | 174 (19.1)           |
| B7                                     | 67 (6.1)              | 50 (5.5)             |
| ECOG score                             |                       |
| 0                                      | 639 (57.7)            | 529 (58.0)           |
| 1                                      | 468 (42.3)            | 383 (42.0)           |
| White blood cells, 10^9/L              |                       |
| 5.9 [4.4-8.2]                          | 5.7 [4.3-7.5]         |
| Platelets, 10^9/L                      | 140 [95-199]          | 140 [94-197]         |
| International normalized ratio         |                       |
| 1.1 [1-1.1]                            | 1.1 [1-1.1]           |
| Alanine aminotransferase, U/L          | 46 [28-57]            | 45 [28-59]           |
| Aspartate aminotransferase, U/L        | 50 [34-73]            | 50 [34-72]           |
| Albumin, g/L                           | 39.4 [36.1-43.2]      | 39.5 [36.2-43.3]     |
| Total bilirubin, µmol/L                | 16.4 [12.0-22.9]      | 16.3 [12.0-22.4]     |
| Blood urea nitrogen, mmol/L            | 5.6 [4.6-6.2]         | 5.6 [4.5-6.3]        |
| Serum creatinine, µmol/L               | 72 [63-83]            | 72 [63-83]           |
| Sessions of TACE                        | 3 [2-4]               | 3 [2-4]              |

TACE: Transarterial chemoembolization; re-TACE: Repeated TACE; HBV: Hepatitis B virus; ECOG: Eastern Cooperative Oncology Group.

Considering that mHAP3 had the highest prognostic value for first TACE and ABCR was correlated with treatment outcome in patients receiving re-TACE, we combined the two scoring systems to stratify the patients treated with TACE. In general, for patients receiving at least two sessions of TACE, 374 patients who were both candidates of first TACE defined by mHAP3 and re-TACE defined by ABCR were considered candidates, while the other 538 patients were non-candidates. According to the survival analysis, candidates achieved better outcomes compared with non-candidates with a median PRTS of 36.6 vs 20.0 mo (P < 0.001) (Figure 4).

### DISCUSSION

The strengths and novelty of the current study are as follows: (1) Validation of the
Figure 2 Receiver operating characteristic curves for evaluating the radiological correlations of the scoring systems. A: Correlations between radiological response and predicting scores; B: Correlations between radiological response and risk stratifications based on the predictive systems for first transarterial chemoembolization. HAP: Hepatoma Arterial-embolization Prognostic; mHAP: Modified HAP; 6&12: Six-and-twelve criteria.

According to the treatment guidelines for HCC, TACE is recommended as standard treatment for intermediate HCC\(^2,3\). However, its clinical application widely exceeds this recommendation in real-world practice, and the heterogeneity of TACE-treated HCC has consequently resulted in the variance in treatment outcomes\(^7-10\). As a prognostic model with indicators including albumin, bilirubin, AFP and tumor diameter, the HAP scoring system could achieve risk stratifications for patients undergoing initial TACE\(^1\). Thereafter, Pinato \textit{et al.}\(^12\) removed serum bilirubin from HAP, as its performance appeared inferior to other parameters, and then proposed the mHAP score. To improve the accuracy of prognosis classification, the mHAP2 was developed with the addition of tumor number as a predictor and adjustment of the cut-off for serum bilirubin\(^13\). Furthermore, the mHAP3 score proposed an individual prognostic model for outcome prediction in a continuous manner for each patient with unresectable HCC\(^14\). However, the HAP system and its modified versions were derived from populations with flexible inclusion criteria and even included patients with MVI. In contrast, our previously proposed 6&12 criteria adopted strict inclusion criteria focusing on the guideline-recommended patients, and excluded those with advanced disease but liver-confined HCC\(^5\). Nevertheless, TACE was mainly performed in unresectable liver-confined disease regardless of intermediate or advanced stages\(^8\). Consequently, we investigated the performance of these prediction systems in such a group of patients. More importantly, the current study determined their associations with radiological response after the first TACE; (3) A comparison of the discriminatory values of these prediction systems in a time-dependent manner; and (4) Integration of the systems in sequence to identify candidates for TACE therapy.

For the evaluation of re-TACE treatment, the ART system consisting of factors related to radiological response, as well as changes in aspartate aminotransferase and Child-Pugh score was used to assess suitability for subsequent TACE\(^15\); nevertheless, the ABCR score selected AFP, BCLC-stage, points increase in Child-Pugh and tumor response as variable parameters, to provide better patient selection for re-TACE\(^16\). According to current analyses, the ABCR system showed a good association with
Table 3  Correlations between radiological response and prognostic systems for first transarterial chemoembolization

| Prognostic system | Score, median [IQR] | Grade | Radiological response, n | Spearman R (P value) | Kappa (P value) |
|-------------------|---------------------|-------|-------------------------|----------------------|-----------------|
| HAP               | 2 [1-2]             | A     | 42 55 26 10 133         | 0.27 (0.028)         | 0.10 (0.020)    |
|                   |                     | B     | 50 157 83 42 332        |                      |                 |
|                   |                     | C     | 39 157 109 92 397       |                      |                 |
|                   |                     | D     | 18 72 81 74 245         |                      |                 |
| mHAP              | 1 [1-2]             | A     | 56 101 43 15 215        | 0.29 (0.028)         | 0.10 (0.020)    |
|                   |                     | B     | 64 198 116 80 458       |                      |                 |
|                   |                     | C     | 25 126 120 96 367       |                      |                 |
|                   |                     | D     | 4 16 20 27 67           |                      |                 |
| mHAP2             | 2 [2-3]             | A     | 13 11 7 2 33            | 0.27 (0.028)         | 0.07 (0.017)    |
|                   |                     | B     | 50 91 53 19 213         |                      |                 |
|                   |                     | C     | 50 180 98 58 386        |                      |                 |
|                   |                     | D     | 36 159 141 139 475      |                      |                 |
| mHAP3             | 0.41 [0.05-0.83]    | A     | 68 129 61 18 276        | 0.27 (0.028)         | 0.10 (0.020)    |
|                   |                     | B     | 48 119 65 46 278        |                      |                 |
|                   |                     | C     | 26 122 72 56 276        |                      |                 |
|                   |                     | D     | 7 71 101 98 227         |                      |                 |
| 6&12              | 9.7 [7.5-12.9]      | A     | 70 114 51 22 257        | 0.39 (0.026)         | 0.14 (0.019)    |
|                   |                     | B     | 58 145 56 46 305        |                      |                 |
|                   |                     | C     | 18 114 85 54 271        |                      |                 |
|                   |                     | D     | 3 68 107 96 274         |                      |                 |

HAP: Hepatoma Arterial-embolization Prognostic; mHAP: Modified HAP; 6&12: Six-and-twelve criteria; ART: Assessment for re-treatment with transarterial chemoembolization; ABCR: Alpha-fetoprotein, BCLC stage, Child-Pugh and Response.

PRTS, but ART showed inferior performance. Although the radiological response and changes in liver function were included in both systems, there may be differences as the ABCR system included the AFP change and BCLC stage. Several studies have reported that the change in AFP after TACE was correlated with treatment effectiveness; and the inclusion of BCLC stage reflected the detailed radiological response, especially the pattern of PD (intrahepatic or extrahepatic progression). Consequently, the ABCR system may be more reliable for the evaluation of treatment outcome following re-TACE.

Finally, considering the predictive abilities of the mHAP3 and ABCR systems, the combination of both could identify candidates for TACE therapy. The significance of this combination includes the following: (1) There has been no such attempt at combining these systems in the past; (2) TACE treatment is an intervention that affects the outcome of patients on the basis of the natural course of the disease. Even if the same patient had different outcomes before and after treatment, the scoring systems designed for pre-treatment (the inability to independently assess the impact of the predictive factor value change on outcomes) and the scoring systems designed for post-treatment (the inability to independently assess the impact of the patient’s underlying status on outcomes) might not be accurate enough to predict outcome, when applied separately; (3) This study selected the best performing scores in the pre-treatment period and post-treatment period, respectively, to achieve the optimum prediction which was more effective than solo prediction; and (4) This combination took advantage of the two scores to make up for their shortcomings: mHAP3 could predict the baseline, but could not guide the clinical decision for the next TACE procedure; ABCR incorporated imaging indicators to better predict survival, but not in the initial assessment of the patient at baseline (this system can only be used after TACE therapy). Combining the above points, the predictive power and clinical application value of this integration of mHAP3 and ABCR are better than each system alone.

There were also several limitations in this study: (1) The retrospective nature of this study may have led to some bias; (2) To compare the HAP, mHAP and mHAP2 systems, we used the quartile values of the continuous scores in mHAP3 and the 6&12 criteria to divide patients into four risk stratification groups, and used their median values to distinguish candidates from non-candidates, which might have
compromised their prediction performance; (3) Given that all patients included in this study were Chinese and the main etiology of HCC was hepatitis B virus infection, caution is necessary in the generalization and extrapolation of our findings; and (4) Study results based on current developed scoring systems need further external validations in a large population from multicenter studies.

In summary, this nationwide multicenter study demonstrated that previously proposed prognostic scoring systems could identify TACE candidates with radiological response and improved OS in unresectable HCC patients treated with first TACE. For re-TACE treatment, the ABCR system, but not the ART system, had a predictive ability for PRTS. Considering the optimal discriminatory abilities of mHAP3 and ABCR in predicting the prognoses of first TACE and re-TACE, these two systems could be sequentially combined to predict treatment outcome of TACE, which may provide useful data for its clinical applications.
Table 4  Comparison of prognostic performance of the predicting systems

| Predicting systems | Candidates/non-candidates | Predicting performance |
|--------------------|---------------------------|------------------------|
|                    | Number of patients | Median survival (mo) | Cox Regression | C-index (95%CI) | LR $^2$ |
|                    |                     |                       | HR (95%CI) | $P$ value |
| For first TACE     |                       |                       |               |            |
| HAP                | 465/642              | 33.8/19.3             | 0.56 (0.47-0.67) | < 0.001  | 0.59 (0.56-0.61) | 43.71 |
| mHAP               | 673/434              | 30.8/16.1             | 0.58 (0.49-0.68) | < 0.001  | 0.59 (0.56-0.61) | 40.85 |
| mHAP 2             | 632/475              | 30.8/17.2             | 0.60 (0.51-0.71) | < 0.001  | 0.58 (0.56-0.60) | 35.24 |
| mHAP 3             | 554/533              | 33.8/17.2             | 0.52 (0.44-0.62) | < 0.001  | 0.60 (0.57-0.62) | 57.51 |
| 6&12               | 562/545              | 31.3/18.5             | 0.61 (0.51-0.72) | < 0.001  | 0.58 (0.56-0.60) | 33.82 |
| For re-TACE        |                       |                       |               |            |
| ART                | 646/266              | 27.0/23.7             | 0.88 (0.72-1.08) | 0.226     | 0.52 (0.49-0.54) | 1.56  |
| ABCR               | 600/312              | 33.1/16.4             | 0.47 (0.39-0.57) | < 0.001  | 0.61 (0.59-0.63) | 57.36 |

TACE: Transarterial chemoembolization; HR: Hazard ratio; CI: Confidence interval; LR: Likelihood ratio; HAP: Hepatoma Arterial-embolization Prognostic; mHAP: Modified HAP; 6&12: Six-and-twelve criteria; ART: Assessment for re-treatment with TACE; ABCR: Alpha-fetoprotein, BCLC stage, Child-Pugh and Response.

ARTICLE HIGHLIGHTS

Research background
Transarterial chemoembolization (TACE) is the most commonly used treatment in patients with unresectable hepatocellular carcinoma (HCC). However, the treatment outcome for such patients varies greatly. Apart from the differences in TACE techniques, the heterogeneity of liver dysfunction, tumor burden and other relevant factors should be carefully considered.

Research motivation
Previously, several prognostic systems have been proposed for risk stratification and clinical decision-making in first TACE and repeated TACE (re-TACE). Nevertheless, it is unknown which model has the highest predictive ability and should be chosen in clinical practice.

Research objectives
In this nationwide multicenter study, we aimed to validate the existing prognostic models for TACE treatment, compare their predictive abilities for overall survival, and finally identify the optimal scoring systems for first TACE and re-TACE in HCC patients.

Research methods
The prognostic values of the Hepatoma Arterial-embolization Prognostic (HAP) scoring system and its modified versions (mHAP, mHAP2 and mHAP3), as well as the six-and-twelve criteria were compared in 1107 unresectable HCC patients treated with at least one session of TACE, while the same analyses were conducted in 912 patients receiving re-TACE to evaluate the ART (assessment for re-treatment with TACE) and ABCR (alpha-fetoprotein, Barcelona Clinic Liver Cancer, Child-Pugh and Response) systems for post re-TACE survival (PRTS).

Research results
With regard to the initial TACE treatment, six-and-twelve criteria had the highest correlation and consistency with radiological response and the mHAP3 criteria had the optimal discrimination value for overall survival. For re-TACE therapy, the ABCR score significantly identified patients with improved PRTS, while the ART system failed to do so. Finally, combining mHAP3 and ABCR systems could discriminate candidates suitable for TACE with improved outcomes compared with non-candidates.

Research conclusions
The results from this study suggest that there is high heterogeneity in patients with unresectable HCC and receiving TACE treatment. The six-and-twelve criteria were closely correlated with radiological response, mHAP3 and ABCR were reliable prognostic systems for first TACE and re-TACE. The sequential combination of these systems would facilitate risk stratification and outcome prediction.

Research perspectives
This study clearly highlights the need for risk stratification of unresectable HCC patients treated with TACE. Comparing the prognostic abilities among the existing scoring systems, we recommend the combined use of mHAP3 and ABCR for survival prediction of HCC patients receiving TACE for the first time, which would not only refine the prognostic stratification but also facilitate individual management. Therefore, future studies focusing on external validations in a large population are necessary.

REFERENCES

1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391: 1301-1314 [PMID: 29307467 DOI: 10.1016/S0140-6736(18)30010-2]
2. European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]
3. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecasis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380 [PMID: 28130846 DOI: 10.1002/hep.29086]
4. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 2016; 64: 106-116 [PMID: 26765068 DOI: 10.1002/hep.28453]
5. Wang Q, Xia D, BAI W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Li J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zhong L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Zhang Y, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Li X, Lv Y, Li K, Yin Z, Xie J, Fan D, Han G, China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol 2019; 70: 893-903 [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013]
6. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferrero V, Piccaglia F, Rasol JL, Sangro B. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348-359 [PMID: 23397536 DOI: 10.1055/s-0032-1329096]
7. Galle PR, Tovoli F, Foerster F, Wörm MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol 2017; 66: 173-183 [PMID: 28323121 DOI: 10.1016/j.jhep.2017.03.007]
8. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35: 2155-2166 [PMID: 25752327 DOI: 10.1111/liv.12818]
9. Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int 2016; 36 Suppl 1: 124-129 [PMID: 26725909 DOI: 10.1111/liv.13028]
10. Sieghart W, Huckle F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indications, and patient selection. J Hepatol 2015; 62: 1187-1195 [PMID: 25815522 DOI: 10.1016/j.jhep.2015.02.010]
11. Kadaliyil L, Benini R, Pallan L, O’Brien J, Marelli L, Yu D, Hacksaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013; 24: 2565-2570 [PMID: 23857958 DOI: 10.1093/annonc/mdt243]
12. Pinato DJ, Arizumi T, Allara E, Jang JW, Smirne C, Kim YW, Kudo M, Pirisi M, Sharma R. Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification. Clin Gastroenterol Hepatol 2015; 13: 1204-8.e2 [PMID: 25528009 DOI: 10.1016/j.cgh.2014.11.057]
13. Park Y, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Park YE, Park JH, Lee YI, Yun HR, Han KH. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int 2016; 36: 100-107 [PMID: 26601386 DOI: 10.1111/liv.12878]
Cappelli A, Cucchetti A, Cabibbo G, Mosconi C, Maida M, Attardo S, Pettinari I, Pinna AD, Golﬁeri R. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int 2016; 36: 729-736 [PMID: 26604044 DOI: 10.1111/liv.13029]

Hucke F, Sieghart W, Pinter M, Grazia`deli I, Vogel W, Müller C, Heinzel H, Waneck F, Trauner M, Peck-Radosavljevic M. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol 2014; 60: 118-126 [PMID: 24012941 DOI: 10.1016/j.jhep.2013.08.022]

Adhoute X, Penaranda G, Naude S, Rasul JL, Perrier H, Bayle O, Monnet O, Beurain P, Bazin C, Pol B, Folgoët GL, Castellani P, Bronowici JP, Bourlière M. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol 2015; 62: 855-862 [PMID: 25463541 DOI: 10.1016/j.jhep.2014.11.014]

Lee YK, Kim SU, Kim DY, Ahn SH, Lee KH, Lee DY, Han KH, Chon CY, Park JY. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer 2013; 13: 5 [PMID: 23382386 DOI: 10.1186/1471-2407-13-5]

Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, Nikolaidis P, Miller FH, Yaghmai V, Baker T, Abecasis M, Benson AB, Mulcahy MF, Omary RA, Salem R. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol 2012; 56: 1112-1120 [PMID: 22245905 DOI: 10.1016/j.jhep.2011.11.020]

Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lopez C, Forner A, Llarch N, Rios J, Ayuso C, Bruix J. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 2013; 58: 2023-2031 [PMID: 23787922 DOI: 10.1002/hep.26596]
